Trial Profile
Phase I/II trial of pexastimogene devacirepvec + sunitinib in patients with renal cancer.
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 01 Apr 2014
Price :
$35
*
At a glance
- Drugs Pexastimogene devacirepvec (Primary) ; Sunitinib
- Indications Renal cancer
- Focus Adverse reactions
- 01 Apr 2014 New trial record